Related Experiment Video

Updated: Jun 16, 2026

Constructing Mutants in Serotype 1 Streptococcus pneumoniae strain 519/43
06:06

Constructing Mutants in Serotype 1 Streptococcus pneumoniae strain 519/43

Published on: September 11, 2020

Effectiveness of pneumococcal conjugate vaccine using a 2+1 infant schedule in Quebec, Canada

Geneviève Deceuninck1, Philippe De Wals, Nicole Boulianne

  • 1Public Health Research Unit, Quebec University Hospital Research Centre, Quebec City, Canada.

The Pediatric Infectious Disease Journal
|February 4, 2010
PubMed

Insights

Pneumococcal conjugate vaccine (PCV) is highly effective in preventing invasive pneumococcal disease (IPD) in children. The vaccine demonstrated significant protection, especially after the recommended doses, confirming its value in pediatric immunization programs.

Area of Science:

  • Pediatric Infectious Diseases
  • Vaccinology
  • Public Health

Background:

  • Pneumococcal conjugate vaccine (PCV) is a key component of routine childhood immunization in Quebec, Canada.
  • Recommended schedules include a 2+1 dosing for infants, with variations for older children.

Purpose of the Study:

  • To estimate the effectiveness of PCV in preventing invasive pneumococcal disease (IPD) among children under 5 years old.
  • To evaluate PCV efficacy based on different dosing schedules.

Main Methods:

  • A case-control study design was employed, including 180 IPD cases and 897 controls.
  • Data collection involved parental interviews and review of immunization records.
  • Unconditional logistic regression models were used to compute PCV effectiveness, adjusting for confounders.

Main Results:

  • Overall PCV effectiveness against any serotype IPD was 60% (95% CI: 38%-75%) with at least one dose.
  • Effectiveness against vaccine serotype IPD reached 92% (95% CI: 83%-96%).
  • Vaccine failures were observed after the first dose, with a significant reduction after the second and no failures after the booster dose in the 2+1 schedule.

Conclusions:

  • PCV demonstrates significant effectiveness in preventing invasive pneumococcal disease in young children.
  • The findings confirm the protective benefits of PCV following 2 and 3 doses, supporting its role in public health strategies.
Abstract

More Related Videos

Experimental Human Pneumococcal Carriage07:47

Experimental Human Pneumococcal Carriage

Published on: February 15, 2013

Capsular Serotyping of Streptococcus pneumoniae Using the Quellung Reaction04:25

Capsular Serotyping of Streptococcus pneumoniae Using the Quellung Reaction

Published on: February 24, 2014

Related Concept Videos

Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Streptococcal Pharyngitis01:27

Streptococcal Pharyngitis

Streptococcal pharyngitis, commonly known as “strep throat,” is an acute infection of the oropharyngeal tissues caused by the Gram‑positive Group A Streptococcus (Streptococcus pyogenes). Transmission occurs primarily through respiratory droplets expelled during coughing, sneezing, or talking.Mechanisms of Host Entry and Immune EvasionUpon entering the host, S. pyogenes adheres to the mucosal epithelial cells of the pharynx via surface proteins, notably lipoteichoic acid and the antiphagocytic...
Vaccinations01:51

Vaccinations

Overview
Cryptococcal Meningitis01:27

Cryptococcal Meningitis

Cryptococcal meningitis is a life-threatening opportunistic infection predominantly associated with HIV/AIDS, accounting for over 100,000 deaths annually worldwide. However, it also affects individuals with other forms of immunosuppression, including those undergoing immunosuppressive therapy, organ transplant recipients, patients with innate immunodeficiencies, and individuals with hematological disorders. The infection is caused mainly by Cryptococcus neoformans and Cryptococcus gattii,...
Smallpox01:24

Smallpox

Smallpox is a severe contagious disease caused by the Variola major virus, a double-stranded DNA member of the Poxviridae family.Variola major transmission occurs primarily via inhalation of virus-laden droplets or direct contact with infectious scabs. The incubation period averages approximately seven days, although it may range from 7 to 17 days depending on the inoculum and host factors.Clinically, the prodromal phase is marked by an abrupt onset of high fever, malaise, headache, and myalgia.
Respiratory Syncytial Virus Disease01:29

Respiratory Syncytial Virus Disease

Human respiratory syncytial virus (RSV) is a widespread pathogen that primarily targets infants and young children but also poses a serious health risk to elderly and immunocompromised individuals. Belonging to the Pneumoviridae family, RSV is a negative-sense, single-stranded RNA virus within the Pneumovirus genus. Its global health burden is significant, with millions of cases annually resulting in hospitalizations and mortality, particularly in resource-limited settings. Although most...